Equal-WT
WhaleScore 2.0
?
ARMISTICE CAPITAL, LLC
4
followers
ยท
Follow
NEW YORK NY
Investment Advisor
Hedge Fund
Activist Investor
Armistice Capital is based out of New York. Armistice Capital is a hedge fund with 3 clients and discretionary assets under management (AUM) of $5,911,150,000 (Form ADV from 2024-05-31). Their last reported 13F filing for Q4 2024 included $7,329,986,329 in managed 13F securities
and a top 10 holdings concentration of 55.65%. Armistice Capital's largest holding is iShares Russell 2000 ETF with shares held of 6,800,000. Whalewisdom has at least 44 13F filings, 87 13D filings, 838 13G filings, and 171 Form 4 filings
Business Description
The advisory business provides investment management services to Advisory Clients and other third parties. The General Partner and Armistice receive consulting assistance services from Prime Brokers, which helps them provide efficient investment management services. However, this arrangement may create actual or potential conflicts of interest, which the General Partner and Armistice will manage by avoiding allocating business or effecting transactions on behalf of the Advisory Clients with the Prime Brokers if it conflicts with their duty to the Advisory Clients.
Investing in the Advisory Clients is considered speculative and is not a complete investment program. It involves significant risk and is only appropriate for experienced and sophisticated individuals who meet certain eligibility criteria, can bear the economic risk of loss, and have limited need for liquidity. There is no guarantee that an Advisory Client will achieve its investment objective.
Investment Strategy
The Feeder Funds aim to achieve long-term capital appreciation through an opportunistic global long/short strategy, primarily investing in equity securities, equity-related instruments, debt investments, and other assets. They emphasize capital preservation and risk mitigation through hedging strategies at both the position and portfolio levels. The Funds focus on strategic value, event, and thematic investment opportunities (both long and short) across various industries, including investments in illiquid assets like securities of non-public companies.
Armistice, the investment manager, utilizes a comprehensive analytical framework to evaluate potential investments. This framework involves assessing market expectations, developing an independent point of view, identifying potential risks, calculating margin of safety, and considering key investment factors like business qualities, prevailing view, upside potential, uniqueness, risk/reward, downside, and catalysts. Armistice prioritizes investments with the greatest asymmetric upside potential and shorting opportunities with the greatest asymmetric downside potential. They determine position size based on absolute downside, expected internal rate of return, and factors like liquidity, industry concentration, correlation, macroeconomic risk, and net long/short exposure. Armistice continuously re-examines investments based on changes in key financial and other developments and exits positions when the target price is achieved, asymmetry is no longer compelling, or their thesis proves incorrect.
Owners
- CORDONE, ANTHONY, JOSEPH - CHIEF FINANCIAL OFFICER
- RUSSELL, MATTHEW, MACKAY - CHIEF OPERATING OFFICER
- BAUTISTA, JOSE YLDEFONSO, MALLONGA - CHIEF COMPLIANCE OFFICER AND DEPUTY CHIEF FINANCIAL OFFICER
- BOYD, STEVEN, JOSEPH - MANAGING MEMBER Click on the Ownership/Private Fund Data tab for more details.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)

2024-12-31
Top Buys (13F)
Name | % Change |
---|---|
IWM iShares Russell 2000 (PUT) | 2.13% |
SPY SPDR S&P 500 ETF TRU (PUT) | 1.64% |
NBIX Neurocrine Bioscienc | 1.33% |
EXAS EXACT Sciences Corp | 1.24% |
ICLR Icon Plc | 1.2% |

2024-12-31
Top Sells (13F)
Name | % Change |
---|---|
CYTK Cytokinetics Inc (CALL) | 1.47% |
CYTK Cytokinetics Inc | 0.76% |
INCY Incyte Corp. | 0.66% |
ALKS Alkermes Plc | 0.65% |
SHAK Shake Shack Inc | 0.42% |

2024-12-31
13F Holdings Summary
Name | $ Change |
---|---|
IWM iShares Russell 2000(PUT) | 20.5% |
SPY SPDR S&P 500 ETF TRU(PUT) | 19.99% |
PTCT PTC Therapeutics Inc | 3.93% |
SUPN Supernus Pharmaceuti | 2.39% |
TVTX Travere Therapeutics | 1.75% |

2024-12-31
13F Activity
Market Value | $7.33b, Prior: $6.25b |
Inflows (Outflows) as % of Total MV | +14.0514% |
New Purchases | 63 stocks |
Added To | 80 stocks |
Sold out of | 90 stocks |
Reduced holdings in | 61 stocks |
Top 10 Holdings % | 55.65% |
Turnover %[1] | 47.66% |
Turnover Alt %[2] | 10.8% |
Time Held Top 20 | 4.75 quarters |
Time Held Top 10 | 5.2 quarters |
Time Held All | 5.75 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.

2024-12-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data

2024-12-31
Analysis

Top 20 equal-weighted holdings. Performance numbers calculated through 2024-12-31